Quick Answer
Mereo BioPharma Group plc reported Stockholders Equity of $40.92 million for fiscal year 2025.
Mereo BioPharma Group plc Stockholders Equity — Annual History
| Fiscal Year | Stockholders Equity | YoY Change |
|---|---|---|
| 2025 | $40.92M | -32.9% |
| 2024 | $60.97M | +20.6% |
| 2023 | $50.54M | -1.7% |
| 2022 | $51.40M | -44.2% |
| 2021 | $92.20M | — |
Quarterly Stockholders Equity
| Quarter Ending | Stockholders Equity | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $46.60M | +164.2% | -14.0% |
| June 30, 2025 | $54.18M | -31.1% | -9.8% |
| March 31, 2025 | $60.08M | +40.3% | -1.5% |
| December 31, 2024 | $60.97M | +20.6% | +184.1% |
| September 30, 2024 | -$72.54M | -232.6% | -192.2% |
| June 30, 2024 | $78.65M | +58.4% | +83.6% |
| March 31, 2024 | $42.84M | -3.5% | -15.2% |
| December 31, 2023 | $50.54M | -1.7% | -7.6% |
- Mereo BioPharma Group plc showed a decrease of -32.9% in Stockholders Equity compared to the prior fiscal year.
- Over the 2021–2025 period, Mereo BioPharma Group plc’s stockholders equity has declined by 55.6% (from $92.20 million to $40.92 million).
- The most recent figure is from Mereo BioPharma Group plc’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 19, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: